AlphaQuest LLC Purchases 50,392 Shares of Astria Therapeutics, Inc. $ATXS

AlphaQuest LLC boosted its position in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) by 354.5% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 64,608 shares of the biotechnology company’s stock after purchasing an additional 50,392 shares during the period. AlphaQuest LLC owned about 0.11% of Astria Therapeutics worth $470,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Affinity Asset Advisors LLC acquired a new position in shares of Astria Therapeutics in the 2nd quarter worth approximately $1,608,000. Panagora Asset Management Inc. acquired a new position in Astria Therapeutics in the second quarter worth $528,000. JPMorgan Chase & Co. grew its holdings in shares of Astria Therapeutics by 4,607.1% during the second quarter. JPMorgan Chase & Co. now owns 1,696,071 shares of the biotechnology company’s stock worth $9,091,000 after purchasing an additional 1,660,039 shares during the last quarter. Bailard Inc. acquired a new stake in shares of Astria Therapeutics in the second quarter valued at $142,000. Finally, Sio Capital Management LLC increased its stake in shares of Astria Therapeutics by 1.0% in the second quarter. Sio Capital Management LLC now owns 318,256 shares of the biotechnology company’s stock valued at $1,706,000 after buying an additional 3,151 shares in the last quarter. 98.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on ATXS shares. Wedbush set a $13.00 price objective on shares of Astria Therapeutics and gave the stock a “neutral” rating in a report on Wednesday, October 15th. Jefferies Financial Group cut shares of Astria Therapeutics from a “buy” rating to a “hold” rating and decreased their price target for the company from $30.00 to $13.00 in a research note on Tuesday, October 14th. HC Wainwright cut shares of Astria Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 16th. Citizens Jmp downgraded Astria Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 15th. Finally, JMP Securities reissued a “market perform” rating on shares of Astria Therapeutics in a research note on Wednesday, October 15th. Two investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $24.50.

Astria Therapeutics Stock Performance

Shares of ATXS stock opened at $12.58 on Friday. The firm’s 50 day moving average price is $12.78 and its two-hundred day moving average price is $10.26. Astria Therapeutics, Inc. has a 52-week low of $3.56 and a 52-week high of $13.29. The stock has a market cap of $718.13 million, a PE ratio of -5.88 and a beta of 0.01.

Astria Therapeutics (NASDAQ:ATXS) last issued its earnings results on Wednesday, November 12th. The biotechnology company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.14). The business had revenue of $0.71 million for the quarter, compared to the consensus estimate of $10.67 million. As a group, sell-side analysts predict that Astria Therapeutics, Inc. will post -1.65 earnings per share for the current fiscal year.

About Astria Therapeutics

Astria Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the development of innovative immunotherapies for oncology and autoimmune diseases. The company leverages proprietary cell engineering platforms to create next‐generation agents that engage T cells and natural killer (NK) cells, with the goal of directing potent and specific immune responses against tumor‐associated antigens or diseased tissues.

Astria’s pipeline encompasses multiple therapeutic candidates across both hematologic and solid tumor indications, as well as autoimmune disorders.